Teva Pharma Industries Ltd ADR vs Biogen: why the prices moved differently

• ▲

  Analysts raise Teva's fair value and initiate with high price targets on CNS transformation Analysts lifted Teva's fair value to $45.30 and initiated coverage with price targets of $50–$55, citing the company's shift toward brain and nerve drugs. This boosts investor confidence and can pull the stock price higher as more analysts recommend buying.

  This is the latest and most direct analyst action that answers why TEVA is moving now.

• ▲

  Teva study shows AUSTEDO preferred by doctors for older tardive dyskinesia patients New data presented at a medical conference shows doctors are most likely to choose Teva's AUSTEDO for older patients with tardive dyskinesia, based on safety and long-term data. This supports continued sales growth for a key Teva drug, which helps earnings and the stock price.

  It provides fresh evidence that Teva's branded drug strategy is gaining traction with prescribers.

• ▲

  Teva bids up to $125 million for BioXcel assets, expanding neuroscience portfolio Teva agreed to be the lead bidder for BioXcel's assets, including the agitation drug IGALMI, for up to $125 million. If approved, this adds a new product to Teva's neuroscience lineup and shows it is investing in growth, which can lift the stock.

  It is a concrete capital move that expands Teva's pipeline and signals confidence in its CNS strategy.

• ▼

  Legal setbacks: Turkey antitrust probe and delayed generic launch for Lupkynis Turkey's competition authority opened an antitrust probe into Teva's patent practices, and Teva agreed to delay its generic version of Aurinia's Lupkynis until 2036. These events create regulatory uncertainty and postpone a potential revenue source, which can weigh on the stock.

  These are new negative regulatory developments that could hurt Teva's reputation and future sales.

Based on 7 stories →

• ▲

  Teva's 'Pivot to Growth' Strategy Accelerates Teva said its growth strategy is accelerating, with debt cut, investment-grade ratings secured ahead of plan, and raised sales targets for key drugs like AUSTEDO and AJOVY. This boosts confidence in future revenue and earnings, supporting a higher stock price.

  This is a major update on Teva's strategic progress, directly impacting investor confidence and future growth prospects.

• ▲

  New Schizophrenia Data Supports Potential Blockbuster New Phase 3 data for TEV-'749, a long-acting schizophrenia treatment, showed high stabilization and low relapse rates. With an FDA decision expected soon, this could become a significant new product, driving future revenue and stock gains.

  This is new clinical data that de-risks a key pipeline asset and highlights near-term regulatory catalyst.

• ▲

  CEO Details Margin Expansion and Cost Savings Teva's CEO outlined a plan to expand gross margin to ~55% and achieve a 30% operating margin by 2027, backed by $700 million in cost savings. The innovative business grew 40% in Q2, showing the strategy is working and boosting profitability outlook.

  This provides concrete financial targets and evidence of margin improvement, key drivers for earnings and stock valuation.

• ▲

  Teva Expands Biosimilar Pipeline with Samsung Bioepis Deal Teva signed a global deal with Samsung Bioepis for up to six biosimilar candidates, adding to its pipeline. This expands Teva's biosimilar portfolio and commercial reach, supporting long-term growth in a high-margin area.

  This is a new partnership that strengthens Teva's biosimilar business, a key growth driver.

Based on 6 stories →

• ▲

  Duvakitug Phase 3 Potential Teva's duvakitug, co-developed with Sanofi, is entering Phase 3 trials for ulcerative colitis and Crohn's disease after strong Phase 2b results. Analysts project peak annual sales of $2–5 billion, which could fuel another 50% stock rally. This pipeline success supports future revenue growth and investor optimism.

  This is a new pipeline catalyst that could significantly boost Teva's long-term revenue and stock price.

• ▲

  Raised 2026 Revenue Guidance Teva raised its 2026 revenue midpoint by $75 million, driven by strong sales of AUSTEDO, AJOVY, and UZEDY. Combined revenue for these three drugs is now expected at about $3.7 billion. This shows Teva's branded drug strategy is working and boosts confidence in future earnings.

  This is a new guidance raise that directly reflects stronger-than-expected demand for Teva's key products.

• ▲

  Direct NYSE Listing and Q2 Sales Beat Teva will replace its ADRs with common stock listed directly on the NYSE starting September 14, which could attract more institutional and retail investors. Q2 sales of $4.1 billion beat estimates, though adjusted EPS missed. The listing change and sales beat drove a 12.3% weekly gain.

  This is a new capital markets event that improves liquidity and investor access, supporting the stock price.

• ▲

  $4.9B Debt Refinancing Teva priced $4.9 billion in new senior notes to refinance higher-cost debt, lowering interest expenses. The new notes carry lower coupons than the debt being redeemed, which will improve cash flow and profitability. This strengthens Teva's balance sheet and supports earnings growth.

  This is a new financing action that reduces interest costs and improves financial flexibility, directly benefiting the stock.

Based on 7 stories →

• ▲

  Teva to acquire BioXcel's IGALMI and BXCL501 assets out of bankruptcy Teva is the stalking horse bidder for BioXcel's assets, including IGALMI and a potential at-home agitation treatment. This adds a commercial drug and a late-stage product to Teva's portfolio, which can boost future revenue. The market initially sent Teva shares down 1%, but the long-term growth potential is positive.

  This is a new acquisition that expands Teva's product portfolio and could drive future revenue.

• ▲

  FDA accepts Alvotech's BLA for subcutaneous Entyvio biosimilar, partnered with Teva Alvotech's application for a subcutaneous version of Entyvio, a treatment for ulcerative colitis and Crohn's disease, has been accepted by the FDA. Teva will commercialize it if approved. This advances Teva's biosimilar pipeline, offering a new revenue stream and strengthening its competitive position in immunology.

  This regulatory milestone for a partnered product expands Teva's biosimilar offerings and future sales potential.

• ◆

  Teva agrees to Medicaid price cuts and MFN pricing in exchange for tariff relief Teva joined nine other drugmakers in deals to lower Medicaid drug prices to match foreign prices, and to supply 45 tons of metronidazole to the government stockpile. In return, Teva gets relief from import tariffs on pharmaceutical ingredients. The price cuts may pressure revenue, but tariff relief and regulatory clarity are positives.

  This is a major new regulatory and pricing agreement that directly affects Teva's revenue and costs.

Based on 6 stories →

• ▲

  Ecopipam NDA submitted for pediatric Tourette syndrome Teva filed for FDA approval of ecopipam, a first-in-class Tourette therapy with strong Phase 3 data. If approved, it would be the first new option in over a decade, adding a new branded revenue stream and boosting long-term growth prospects.

  This is a new pipeline catalyst that could drive future sales and shows Teva's innovative focus.

• ▲

  Austedo data reinforces growth driver status New clinical data shows Austedo improves symptoms in most tardive dyskinesia and Huntington's chorea patients. As Teva's biggest growth driver, strong data supports continued sales growth, which is key to offsetting generic declines.

  This reinforces the growth story for Teva's top branded drug, directly impacting revenue outlook.

• ▲

  European launch of Eylea biosimilar expands market Teva launched Ahzantive, a biosimilar to Eylea, in several European countries. This expands its biosimilar portfolio and adds a new source of revenue in ophthalmology, supporting the company's shift toward higher-margin products.

  New product launch in a major market adds incremental revenue and shows execution of biosimilar strategy.

• ▲

  Global licensing deal for Ocrevus biosimilar Teva signed a deal with Polpharma Biologics to commercialize a proposed Ocrevus biosimilar worldwide. This expands Teva's biosimilar pipeline and supports its Pivot to Growth strategy, with Teva handling regulatory and commercialization.

  This strategic deal adds a high-value biosimilar to Teva's pipeline, enhancing long-term growth potential.

Based on 6 stories →

• ▲

  10 Phase III programs signal growth beyond MS Biogen said it has 10 late-stage trials with results starting in Q4, shifting focus from its shrinking MS business to new drugs like LEQEMBI and ZURZUVAE. This raises hopes for future revenue growth, supporting the stock.

  This is the main new strategic update that could drive long-term growth and investor optimism.

• ▲

  Japan approves at-home Leqembi injection Japan cleared a subcutaneous form of Leqembi, allowing weekly at-home dosing instead of hospital infusions. This is the third country to approve it, making the Alzheimer's drug easier to use and expanding its market, which could boost sales.

  New regulatory approval directly expands the addressable market for a key growth drug.

• ▼

  Medicare price crackdown may limit Zurzuvae launch A study warns that U.S. efforts to align Medicare drug prices with cheaper countries could push companies to raise prices or withdraw medicines elsewhere. Biogen's CEO said Zurzuvae will launch in only a few European countries to offset lost U.S. revenue, signaling a hit to its global sales potential.

  This is a new regulatory risk that could reduce future revenue from a key product.

• ▲

  Biogen posts best quarterly revenue beat in group Biogen's Q2 revenue of $2.74 billion rose 3.4% and beat expectations by 12.1%, the strongest among 11 therapeutics stocks. This shows better-than-expected commercial execution, which can lift investor confidence.

  New earnings data confirms strong performance relative to peers, a positive fundamental signal.

Based on 6 stories →

• ◆

  RayThera acquisition closes, EPS guidance cut Biogen completed its purchase of RayThera, adding an early-stage immunology drug. But acquisition charges forced it to slash 2026 adjusted EPS guidance to $12–$13 from $14.25–$15.25. The revenue outlook rose to mid-single-digit growth, but the profit hit is what investors will feel near-term.

  This is the single biggest new event, directly changing Biogen's earnings outlook and explaining the stock's mixed reaction.

• ▲

  China approves at-home LEQEMBI injection China approved a subcutaneous (under-the-skin) form of LEQEMBI for early Alzheimer's, allowing weekly at-home dosing instead of hospital infusions. This is the second country to clear it, after the U.S. in July. It widens the market and makes treatment far easier for patients.

  A new regulatory approval in a huge market (17 million early Alzheimer's patients in China) directly boosts the long-term sales potential of Biogen's key Alzheimer's drug.

• ▲

  Five Phase 3 readouts ahead; shares seen as undervalued Biogen raised its non-GAAP EPS guidance and has five late-stage trial results coming in lupus, transplant and rare diseases. Shares trade about 10% below the average analyst target, with a 54% one-year total return. But competition in MS and Alzheimer's, plus launch risks for LEQEMBI and ZURZUVAE, remain real concerns.

  This gives the forward-looking catalyst picture and the valuation gap, which is central to why investors are watching Biogen now.

• ▲

  Biogen adopts Veeva's AI-powered CRM globally Biogen selected Veeva's Vault CRM suite, an AI-driven sales and safety platform, for global use. This is an operational upgrade, not a direct revenue driver, but it signals Biogen is investing in modern commercial infrastructure. It also deepens a multi-year software relationship, which can lower long-term selling costs.

  It shows Biogen is modernizing its commercial operations with AI, a modest but real positive for efficiency and execution.

Based on 7 stories →

• ▲

  Q2 beat on rare-disease and Leqembi demand Biogen's second-quarter profit and revenue beat expectations, helped by strong sales of rare-disease medicines and a 15% rise in Leqembi sales to about $184 million. This shows the core business is growing, which supports the stock.

  This is the main new event of the period and directly explains why Biogen is moving.

• ▼

  2026 profit guidance cut on Apellis charges Biogen slashed its 2026 adjusted earnings forecast to $12–$13 per share from $14.25–$15.25, largely due to $3.85 per share of acquisition-related charges, including 85 cents from the $5.6 billion Apellis buyout. This weighs on the stock.

  This is the key counterweight that explains why the stock isn't rising more despite the earnings beat.

• ▲

  Leqembi real-world data and sales momentum A real-world study showed over 75% of early Alzheimer's patients remained stable on Leqembi, and Q2 sales grew 43% excluding one-time stockpiling. This supports adoption and future sales, a positive for Biogen as Eisai's partner.

  This new evidence reinforces the commercial case for Biogen's key Alzheimer's drug.

• ▲

  Pipeline progress: Gazyva priority review, litifilimab enrollment The FDA granted priority review to Gazyva for a rare kidney disease, and Biogen's lupus drug litifilimab completed Phase III enrollment with results due in H2 2026. These advance the pipeline and offer future growth, supporting the stock.

  These are new regulatory and clinical milestones that add to the long-term growth story.

Based on 12 stories →

• ▲

  FDA approves at-home subcutaneous Leqembi The FDA approved Leqembi Iqlik, a once-weekly under-the-skin injection for early Alzheimer's, allowing at-home dosing. This removes the need for IV infusions, which should boost patient demand and sales. Biogen shares rose on the news.

  This is a major new approval that directly expands the market for Biogen's key Alzheimer's drug.

• ▲

  Diranersen shows 42% cognitive decline slowdown Biogen presented Phase 2 data showing its tau-targeting drug diranersen slowed cognitive decline by 42% on one measure and cut tau tangles. This suggests a potential new Alzheimer's treatment, lifting hopes for future growth.

  Positive efficacy data from a new drug candidate is a key driver of investor optimism.

• ▼

  Dosing paradox clouds diranersen data, stock tumbles The same Phase 2 trial missed its main goal because the lowest dose worked best while higher doses did worse. This unexplained 'dosing paradox' raised doubts about the drug's effectiveness and path forward, causing Biogen shares to fall nearly 9%.

  This negative twist directly caused a sharp sell-off and creates uncertainty about a key pipeline asset.

• ▲

  Truist upgrade highlights Alzheimer's pipeline A Truist analyst upgrade pointed to optimism for Biogen's Alzheimer's pipeline, helping the stock gain even as the broader market fell. This analyst view reinforced positive sentiment around the company's Alzheimer's efforts.

  Analyst upgrade is a fresh catalyst that supported the stock price during the period.

Based on 7 stories →

• ▲

  RayThera acquisition expands immunology pipeline Biogen agreed to buy private biotech RayThera for up to $1 billion, mostly in future milestone payments. This adds early-stage anti-inflammatory drugs to its pipeline, a bet on future growth. Investors liked the move, helping push the stock up.

  This is the main new event driving positive sentiment and shows Biogen's strategy to replace lost revenue.

• ▲

  FDA Breakthrough Therapy designation for Salanersen Biogen's spinal muscular atrophy drug candidate Salanersen received FDA Breakthrough Therapy status, which speeds up development and review. This signals the drug may be effective and could become a future growth driver, boosting investor confidence.

  This is a new regulatory win that supports the bull case for Biogen's pipeline.

• ▼

  Securities fraud investigation over CELIA study Law firm Pomerantz is investigating Biogen for possible securities fraud related to its Phase 2 CELIA study, which missed its main goal but was described positively. This legal risk could lead to fines or lawsuits, weighing on the stock.

  This is a new negative event that introduces regulatory and legal uncertainty.

• ▼

  Legacy drug sales decline continues to drag Biogen's older multiple sclerosis drugs and Spinraza are losing sales to generics and rivals. Newer drugs are growing but not fast enough to fully offset the decline. This ongoing pressure limits overall revenue growth and keeps a lid on the stock.

  This is a key fundamental challenge that offsets positive pipeline news and explains why the stock isn't higher.

Based on 6 stories →